课题基金 / 基金详情

LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE

LCCC 0310 DENDRITIC CELL VACCINE GIVEN WITH TRASTUZUMAB AND VINORELBINE
LCCC 0310 树突状细胞疫苗，含曲妥珠单抗和长春瑞滨
批准号：
7625547
负责人：
Jonathan S. Serody
金额：
$0.53万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
项目状态：
已结题
起止时间：
2006-12-01 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7625547
关键词：
AntibodiesComputer Retrieval of Information on Scientific Projects DatabaseDendritic Cell VaccineDendritic CellsFundingGrantInstitutionPurposeResearchResearch PersonnelResourcesSourceTestingTrastuzumabTrastuzumab/VinorelbineUnited States National Institutes of HealthVinorelbinechemotherapykillingsneoplastic cell

项目摘要

项目成果

Jonathan S. Serody的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是测试是否给予树突状细胞与化疗（称为长春瑞滨）和抗体（称为曲妥珠单抗），这是有效地杀死肿瘤细胞，将更有效地比以前发现的给予化疗和抗体而不使用树突状细胞。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test whether giving dendritic cells with chemotherapy (called vinorelbine) and an antibody (called trastuzumab), which are effective in killing tumor cells, will be more effective than what has been previously found with giving the chemotherapy and antibody without using dendritic cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UNC Immunotherapy Training Grant (IM-TAG)
SToP Cancer SPORE: Career Enhancement Program
SToP Cancer SPORE: Career Enhancement Program
Enhancing Innate Immune Reconstitution Post Allogeneic HSCT.